The Ki-67 protein: From the known and the unknown

Journal of Cellular Physiology

Volumn 182, Issue 3, 2000, Pages 311-322

  Scholzen, Thomas ^a   Gerdes, Johannes ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR PROTEIN;

CELL CYCLE PHASE; CELL DIVISION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; RNA SPLICING;

BREAST NEOPLASMS; CELL CYCLE; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033984235     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9     Document Type: Review

References (95)

1. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjänen K. 1997. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 32:410-415.
2. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. 1998. The p53 network. J Biol Chem 273:1-4.
3. Alison MR. 1995. Assessing cellular proliferation: what's worth measuring? Hum Exp Toxicol 14:935-944.
4. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF. 1995. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72:1259-1266.
5. Arellano M, Moreno S. 1997. Regulation of CDK/cyclin complexes during the cell cycle. Int J Biochem Cell Biol 29:559-573.
6. Bai XZ, Masters JR, O'Donoghue N, Kirby R, Pan LX, Young M, Stafford M, Parkinson MC. 1999. Prognostic markers in clinically localised prostate cancer. Int J Oncol 14:785-791.
7. Bettencourt M-C, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. 1996. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 156:1064-1068.
8. Borre M, Bentzen SM, Nerström B, Overgaard J. 1998. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 159:1609-1614.
9. Braun N, Papadopoulos T, Müller-Hermelink HK. 1988. Cell cycle dependent distribution of the proliferation-associated Ki-67 antigen in human embryonic lung cells. Virchows Arch B Cell Pathol Incl Mol Pathol 56:25-33.
10. 1 cells. Chromosome Res 6:13-24.
11. Bruno S, Darzynkiewicz Z. 1992. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif 25:31-40.
12. Bruno S, Crissman HA, Bauer KD, Darzynkiewicz Z. 1991. Changes in cell nuclei during S phase: progressive chromatin condensation and altered expression of the proliferation-associated nuclear proteins Ki-67, cyclin (PCNA), p105, and p34. Exp Cell Res 196:99-106.
13. Bruno S, Gorczyca W, Darzynkiewicz Z. 1992. Effect of ionic strength in immunocytochemical detection of the proliferation associated nuclear antigens p120, PCNA, and the protein reacting with Ki-67 antibody. Cytometry 13:496-501.
14. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch MJ. 1996. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 178:437-441.
15. Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G. 1998. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 29:949-954.
16. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J. 1992. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363.
17. Chelsky D, Ralph R, Jonak G. 1989. Sequence requirements for synthetic peptide-mediated translocation to the nucleus. Mol Cell Biol 9:2487-2492.
18. Cher ML, Stephenson RA, James BC, Carroll PR. 1996. Cellular proliferative fraction of metastatic lymph nodes predicts survival in stage D1 (TxN+M0) prostate cancer. J Urol 155:1674-1677.
19. Clahsen PC, van de Velde CJ, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. 1998. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 16:470-479.
20. Darzynkiewicz Z, Traganos F. 1982. RNA content and chromatin structure in cycling and noncycling cell populations studied by flow cytometry. In: Padilla P, McCarty KS, editors. Genetic expression in the cell cycle. New York: Academic Press. p 103-128.
21. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H, Höfler H. 1997. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75:1525-1533.
22. Dingwall C, Laskey RA. 1991. Nuclear targeting sequences - a consensus? Trends Biochem Sci 16:478-481.
23. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. 1996. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res 2:147-154.
24. Drach J, Gattringer C, Glassl H, Drach D, Huber H. 1992. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma. Hematol Oncol 10:125-134.
25. 2 phase. Cell Tissue Kinet 17:453-463.
26. Duchrow M, Schlüter C, Wohlenberg C, Flad H-D, Gerdes J. 1996. Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 29:1-12.
27. du Manoir S, Guillaud P, Camus E, Seigneurin D, Brugal G. 1991. Ki-67 labeling in postmitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry 12:455-463.
28. Evans T, Rosenthal ET, Youngblom J, Distel D, Hunt T. 1983. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33:389-396.
29. Gerdes J, Schwab U, Lemke H, Stein H. 1983. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20.
30. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. 1984. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715.
31. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad H-D. 1991. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867-873.
32. Gerlach C, Sakkab DY, Schulzen T, Daßler R, Alison MR, Gerdes J. 1997a. Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology 26:573-578.
33. Gerlach C, Golding M, Larue L, Alison MR, Gerdes J. 1997b. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 77:697-698.
34. Graña X and Reddy EP. 1995. Cell cycle control in mammalian cells: role of cyclins, cyclin-dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11: 211-219.
35. Graña X, Garriga J, and Mayol X. 1998. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 17:3365-3383.
36. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. 1994. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting. Science 265:103-106.
37. Haerslev, T, Jacobsen GK, Zedeler K. 1996. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37:101-113.
38. Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R. 1996. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the "Ki-67" proteins. Cell Prolif 29:413-425.
39. Herskowitz I. 1987. Functional inactivation of genes by dominant negative mutations. Nature 329:219-222.
40. Heslin MJ, Cordon-Cardo C, Lewis JJ, Woodruff JM, Brennan MF. 1998. Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma. Cancer 83:490-497.
41. Heyden TS. 1997. Zellbiologische Untersuchungen zu intrazellulärem Transport, Funktion und Regulation des proliferations-assoziierten Antigens Ki-67. Doctoral thesis at the Freie Universität Berlin, Germany.
42. Hofmann K, Bucher P. 1995. The FHA domain: a putative nuclear signalling domain found in protein kinases and transcription factors. Trends Biochem Sci 20:347-349.
43. Huuhtanen RL, Blomqvist CP, Wiklund TA, Böhling TO, Virolainen MJ, Tukiainen EJ, Tribukait B, Andersson LC. 1999. Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma. Br J Cancer 79:945-951.
44. Jansen RL, Hupperets PS, Arends JW, Joosten-Achjanie SR, Volovics A, Schouten HC, Hillen HF. 1998. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 78:460-465.
45. Jensen V, Ladekarl M, Holm-Nielsen P, Melsen F, Sœrensen FB. 1995. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol 176:343-352.
46. Kearsey SE, Labib K. 1998. MCM proteins: evolution, properties, and role in DNA replication. Biochim Biophys Acta 1398:113-136.
47. Keshgegian AA, Cnaan A. 1995. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104:42-49.
48. Keshgegian AA, Johnston E, Cnaan A. 1998. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 110:443-449.
49. Kill IR. 1996. Localisation of the Ki-67 antigen within the nucleolus: evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci 109:1253-1263.
50. Kosco-Vilbois MH, Zentgraf H, Gerdes J, Bonnefoy J-Y. 1997. To 'B' or not to 'B' a germinal center? Immunol Today 18:225-230.
51. Kubbutat MH, Cattoretti G, Gerdes J, Key G. 1994. Comparison of monoclonal antibodies PC10 and MIB 1 on microwave-processed paraffin sections. Cell Prolif 27:553-559.
52. Lazebnik YA, Medvedeva ND, Zenin W. 1991. Reversible G2 block in the cell cycle of Ehrlich ascites carcinoma cells. Exp Cell Res 195: 247-254.
53. Lee D, Prowse DM, Brissette JL. 1999. Association between mouse nude gene expression and the initiation of epithelial terminal differentiation. Dev Biol 208:362-374.
54. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
55. Lew DJ, Kornbluth S. 1996. Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8:795-804.
56. Lloyd RV. 1998. Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. Am J Clin Pathol 109:245-247.
57. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, Boisseau MR. 1991. Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry 12:42-49.
58. Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P, Boisseau MR. 1994. The labelling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to the DNA. Exp Cell Res 210:145-153.
59. Mayol X and Graña X. 1997. pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. Prog Cell Cycle Res 3:157-169.
60. Miguel-Garcia A, Matutes E, Tarin F, Garcia-Talavera J, Miguel-Sosa A, Carbonell F, Catovsky D. 1995. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy. J Clin Pathol 48:835-839.
61. Molino A, Micciolo R, Turazza M, Bonetti F, Piubello Q, Bonetti A, Nortilli R, Pelosi G, Cetto GL. 1997. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 74:433-437.
62. Moul JW, Bettencourt M-C, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Bauer JJ. 1996. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 120:159-166.
63. Paggi MG, Baldi A, Bonetto F, Giordano A. 1996. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 62:418-430.
64. Pinder, SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blarney RW, Ellis IO. 1995. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146-149.
65. Pines J. 1995. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 308:697-711.
66. Prosperi E. 1997. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Prog Cell Cycle Res 3:193-210.
67. Rajewsky K, Gu H, Kühn R, Betz UA, Müller W, Roes J, Schwenk F. 1996. Conditional gene targeting. J Clin Invest 98:600-603.
68. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K, Dieras V, Pouillart P, Sastre-Garau X. 1998. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 79:27-33.
69. Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R, Coindre JM. 1997. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma: a multivariate study. Am J Pathol 150:1997-2007.
70. Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, Fernö M, Parwaresch R, Alm P. 1999. Correlation between p53, c-erbB-2, and topoisomerase IIa expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 187:207-216.
71. Saraste M, Sibbald PR, Wittinghofer A. 1990. The P-loop - a common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 15: 430-434.
72. Sasaki K, Murakami T, Kawasaki M, Takahashi M. 1987. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 133:579-584.
73. Savino TM, Bastos R, Jansen E, Hernandez-Verdun D. 1999. The nucleolar antigen Nop52, the human homologue of the yeast ribosomal RNA processing RRP1, is recruited at late stages of nucleologenesis. J Cell Sci 112:1889-1900.
74. Sawhney N, Hall PA. 1992. Ki67 - structure, function, and new antibodies. J Pathol 168:161-162.
75. Scalzo DA, Kallakury BV, Gaddipati RV, Sheehan CE, Keys HM, Savage D, Ross JS. 1998. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol 109:163-168.
76. Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad H-D, Gerdes J. 1993. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 123:513-522.
77. Scholzen T, Dimmler C, Wohlenberg C, Flad H-D, Gerdes J. 1997. Novel splice forms of the Ki-67 mRNA (Abstract). Eur J Cell Biol 72(Suppl. 44):40-40.
78. Schwarting R. 1993. Little missed markers and Ki-67. Lab Invest 68:597-599.
79. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. 1996. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69: 135-141.
80. Shi S-R, Cote RJ, Hawes D, Thu S, Shi Y, Young LL, Taylor CR. 1999. Calcium-induced modification of protein conformation demonstrated by immunohistochemistry: what is the signal? J Histochem Cytochem 47:463-469.
81. Silver PA. 1991. How proteins enter the nucleus. Cell 64:489-497.
82. Starborg M, Gell K, Brundell E, Höög C. 1996. The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 109:143-153.
83. Stattin P, Damber J-E, Karlberg L, Bergh A. 1997. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 157:219-222.
84. Stiegler P, Kasten M, Giordano A. 1998. The RB family of cell cycle regulatory factors. J Cell Biochem Suppl 30/31:30-36.
85. Sun Z, Hsiao J, Fay DS, Stern DF. 1998. Rad53 FHA domain associated with phosphorylated Rad9 in the DNA damage checkpoint. Science 281:272-274.
86. Tada S, Blow JJ. 1998. The replication licensing system. Biol Chem 379:941-949.
87. Takagi M, Matsuoka Y, Kurihara T, Yoneda Y. 1999. Chmadrin: a novel Ki-67 antigen-related perichromosomal protein possibly implicated in higher order chromatin structure. J Cell Sci 112:2463-2472.
88. Ueda T, Aozasa K, Tsujimoto M, Ohsawa M, Uchida A, Aoki Y, Ono K, Matsumoto K. 1989. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 63:1607-1611.
89. van Dierendonck JH, KeijzerR, van de Velde CJ, Cornelisse CJ. 1989. Nuclear distribution of the Ki-67 antigen during the cell cycle: comparison with growth fraction in human breast cancer cells. Cancer Res 49:2999-3006.
90. van Oijen MG, Medema RH, Slootweg PJ, Rijksen G. 1998. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol 110:24-31.
91. Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ, Ramaekers FC. 1989a. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J Cell Sci 92:123-130.
92. Verheijen R, Kuijpers HJ, van Driel R, Beck JL, van Dierendonck JH, Brakenhoff GJ, Ramaekers FC. 1989b. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 92:531-540.
93. Veronese SM, Maisano C, Scibilia J. 1996. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res 16:2717-2722.
94. Wei W, Nurse P, Broek D. 1993. Yeast cells can enter a quiescent state through G1, S, G2, or M phase of the cell cycle. Cancer Res 53:1867-1870.
95. Weikel W, Brumm C, Wilkens C, Beck T, Knapstein PG. 1995. Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev 19:446-450.